文献速递糖尿病

达格列净在儿童和年轻成人2型糖尿病患者中的疗效与安全性:一项前瞻性、多中心、随机、平行组、3期研究

Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-04-01

这项多中心、安慰剂对照、双盲、随机3期研究在5个国家30个中心纳入10-24岁2型糖尿病患者72例,按1:1随机接受达格列净10 mg或安慰剂治疗24周,随后28周开放标签安全性扩展。意向治疗分析中,24周HbA1c变化组间差异为-0.75%(95%CI -1.65至0.15;p=0.10),未达统计学显著;符合方案集敏感性分析组间差异为-1.13%(95%CI -1.99至-0.26;p=0.012)。未发现新的安全性信号,严重低血糖风险低。

要点

  • 意向治疗分析中,达格列净组24周HbA1c变化与安慰剂组差异为-0.75%(95%CI -1.65至0.15;p=0.10),未达统计学显著。
  • 符合方案集敏感性分析中,达格列净组24周HbA1c变化与安慰剂组差异为-1.13%(95%CI -1.99至-0.26;p=0.012)。
  • 24周内达格列净组不良事件发生27例(69%),安慰剂组19例(58%);无糖尿病酮症酸中毒不良事件。

核心结论

  • 在接受标准治疗的儿童、青少年和年轻成人2型糖尿病患者中,加用达格列净后HbA1c变化的意向治疗分析主要结局未达统计学显著。
  • 符合方案集敏感性分析显示两组HbA1c变化差异有统计学意义。
  • 未发现新的安全性信号,严重低血糖风险低。

研究设计与样本

  • 多中心、安慰剂对照、双盲、随机3期研究,在5个国家(匈牙利、以色列、墨西哥、俄罗斯和美国)的30个中心开展。
  • 纳入10-24岁、HbA1c 6.5-11%(48-97 mmol/mol)的2型糖尿病患者72例,按1:1随机接受口服达格列净10 mg或安慰剂治疗24周双盲期,随后28周开放标签安全性扩展期所有参与者均接受达格列净。
  • 主要结局为基线至24周HbA1c变化的组间差异(意向治疗分析),并对符合方案集人群进行预设敏感性分析。

主要发现

  • 2016年6月22日至2019年3月15日随机分配72例参与者(39例达格列净组,33例安慰剂组),平均年龄16.1岁(SD 3.3),其中19例(26%)年龄18-24岁。
  • 意向治疗分析24周后,达格列净组HbA1c平均变化-0.25%(95%CI -0.85至0.34;-2.7 [-9.3至3.7] mmol/mol),安慰剂组0.50%(-0.18至1.17;5.5 [-2.0至12.8] mmol/mol),组间差异-0.75%(95%CI -1.65至0.15;-8.2 [-18.0至1.6] mmol/mol;p=0.10)。
  • 符合方案集敏感性分析(达格列净组34例,安慰剂组26例)24周后,达格列净组HbA1c平均变化-0.51%(-1.07至0.05;-5.6 [-11.7至0.5] mmol/mol),安慰剂组0.62%(-0.04至1.27;6.8 [-0.4至13.9] mmol/mol),组间差异-1.13%(-1.99至-0.26;-12.4 [-21.8至-2.8] mmol/mol;p=0.012)。
  • 24周内不良事件在达格列净组27例(69%)和安慰剂组19例(58%)中发生,52周内接受达格列净的参与者中29例(74%)发生不良事件。
  • 24周内低血糖在达格列净组11例(28%)和安慰剂组6例(18%)中发生,52周内接受达格列净的参与者中13例(33%)发生;无严重不良事件,无糖尿病酮症酸中毒不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since there are few treatment options for young people with type 2 diabetes, we aimed to assess the efficacy and safety of dapagliflozin as add-on therapy in children, adolescents, and young adults with type 2 diabetes receiving metformin, insulin, or both. METHODS: This multicentre, placebo-controlled, double-blind, randomised phase 3 study was undertaken at 30 centres in five countries (Hungary, Israel, Mexico, Russia, and the USA). Participants aged 10-24 years with type 2 diabetes and HbA1c concentration of 6·5-11% (48-97 mmol/mol) were randomly assigned 1:1 to oral dapagliflozin 10 mg or placebo during a 24 week double-blind period, which was then followed by a 28 week open-label safety extension in which all participants received dapagliflozin. Participants and study personnel were masked and participants were randomly assigned treatment (placebo or study drug) using an interactive web and voice response system. The primary outcome was between-group differences in change in HbA1c concentration from baseline to 24 weeks (intention-to-treat analysis). A prespecified sensitivity analysis of the primary outcome was also assessed in the per-protocol population, which included only protocol-compliant participants. This trial is registered with ClinicalTrials.gov, NCT02725593. FINDINGS: Between June 22, 2016, and March 15, 2019, 72 participants (19 [26%] of whom were aged 18-24 years) were randomly assigned (39 to dapagliflozin and 33 to placebo). Mean age was 16·1 (SD 3·3) years. In the intention-to-treat analysis, after 24 weeks, mean change in HbA1c concentration was -0·25% (95% CI -0·85 to 0·34; -2·7 [-9·3 to 3·7] mmol/mol) for dapagliflozin and 0·50% (-0·18 to 1·17; 5·5 [-2·0 to 12·8] mmol/mol) for placebo. The between-group difference was -0·75% (95% CI -1·65 to 0·15; -8·2 [-18·0 to 1·6] mmol/mol; p=0·10). In a sensitivity analysis in the per-protocol population (34 in the dapagliflozin group and 26 in the placebo group) after 24 weeks, mean change was -0·51% (-1·07 to 0·05; -5·6 [-11·7 to 0·5] mmol/mol) for dapagliflozin and 0·62% (-0·04 to 1·27; 6·8 [-0·4 to 13·9] mmol/mol) for placebo. The between-group difference was -1·13% (-1·99 to -0·26; -12·4 [-21·8 to -2·8] mmol/mol; p=0·012). Adverse events occurred in 27 (69%) dapagliflozin-assigned participants and 19 (58%) placebo-assigned participants over 24 weeks, and in 29 (74%) participants who received dapagliflozin over 52 weeks. Hypoglycaemia occurred in 11 (28%) dapagliflozin-assigned and six (18%) placebo-assigned participants who received dapagliflozin over 24 weeks and in 13 participants (33%) who received dapagliflozin over 52 weeks; none were considered as serious adverse events. No adverse events of diabetic ketoacidosis occurred. INTERPRETATION: The primary outcome of change in HbA1c concentration was not significant in the intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes receiving dapagliflozin in addition to standard-of-care treatment. A prespecified sensitivity analysis of protocol-compliant participants showed a significant difference in HbA1c concentration between groups. No new safety signals were identified and there was a low risk of severe hypoglycaemia. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Tamborlane WV, Laffel LM, Shehadeh N, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022. PMID: 35378069. doi:10.1016/S2213-8587(22)00052-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。